Salute e Benessere

First Patient Dosed for MRCT Phase 3 Study on First-Line LS-SCLC of Henlius…

HANSIZHUANG is the first innovative mAb developed by Henlius. It has been approved by the NMPA for the treatment of MSI-H solid tumours, non-small cell lung cancer (sqNSCLC) and ES-SCLC and esophageal squamous cell carcinoma (ESCC) and has since seen benefits in 40,000 patients in China. Regarding unmet clinical needs as a core, Henlius covers the full range of first-line treatments of LC. Two global multi-centre phase 3 clinical trials regarding sqNSCLC and ES-SCLC have been conducted in China…
PR Newswire
25/10/2023

Cumulus Neuroscience Presents Data at CTAD 2023 Annual Meeting

The poster featuring data generated from a Phase Ib study in Alzheimer's Disease (AD) sponsored by INmune Bio titled, "Feasibility of the Cumulus electrophysiological neurocognitive platform to enable de-centralized trials in Alzheimer's Disease," demonstrated that the Cumulus Neuroassessment platform can be frequently and accurately used by patients living with mild to moderate AD in the home over long periods of time (e.g., >3 months) including 'burst' measurement periods in-lab…
PR Newswire
25/10/2023

Global Diabetes Care Market Size Expected To Reach $41.71 Billion By 2027

Emergen Research continued: "Hospitals & clinics segment revenue is expected to expand at a rapid CAGR in the Global Diabetes Care Market during the forecast period (2028)… The Global Diabetes Care Market is segmented into hospitals & clinics, home care settings, and diagnostic centers. The hospitals & clinics segment dominated other end-use segments and accounted for largest revenue share in (recent years). An increasing number of hospital admissions of diabetes patients is…
PR Newswire
25/10/2023

FDA Meeting Feedback Puts Turn Biotechnologies on Track to be First Longevity…

"We were gratified at the strong alignment between Turn Bio's approach to developing TRN-001 and the comments of FDA reviewers," said Anja Krammer, CEO of Turn Bio. "We look forward to advancing our pre-clinical work as we work toward IND submission." "We were gratified at the strong alignment between Turn Bio's approach to developing TRN-001 and the comments of FDA reviewers," saidAnja Krammer, CEO of Turn Bio. "We look forward to advancing our pre-clinical…
PR Newswire
25/10/2023

Centessa Pharmaceuticals Announces Preclinical Data Supporting ORX750's…

- Preclinical data demonstrated significant activity at low doses of ORX750 in highly predictive translational models of Narcolepsy Type 1 (NT1) - ORX750 advancing in IND-enabling studies; Clinical proof of concept data planned for 2024BOSTON and LONDON, Oct.25, 2023(GLOBE NEWSWIRE) --Centessa Pharmaceuticals plc(Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced a...
Nasdaq GlobeNewswire
25/10/2023

ESAOTE's new S-scan Open redefines excellence in magnetic resonance imaging

S-scan Openis the result of constant commitment to research and development and of carefully listening to market needs and user feedback from all over the world. Introducing anupdated versionof its best-selling MRI system is a new challenge for Esaote to provide evenmore advanced performanceand to enhance the operator experience and patient comfort during diagnostic examinations. " With S-scan Open,we have relied on Esaote's latest technology, in terms of the hardware...
PR Newswire
25/10/2023

Metabolon and Genomics England Announce Partnership to Characterize Hundreds of…

Rare diseases are incredibly difficult to analyze and can often take years to obtain a definitive diagnosis, if at all. There are three hundred and fifty million people worldwide suffering from rare diseases. 75% of rare diseases affect children, often leading to poor quality of life and early mortality. Rare diseases are incredibly difficult to analyze and can often take years to obtain a definitive diagnosis, if at all. There are three hundred and fifty million people worldwide suffering...
PR Newswire
25/10/2023

Curium and PIUR IMAGING Announce Thyroid Imaging Partnership in Germany to…

Under the terms of the partnership agreement, PIUR IMAGING will provide and continuously develop the hardware and software solution, with Curium responsible for the exclusive distribution of the product in nuclear medicine in Germany. Ciril Faia, CEO SPECT Europe at Curium, commented:“The partnership announced today with PIUR IMAGING in Germany represents an exciting leap forward in medical imaging, with the potential to impact cancer patient care and treatment outcomes. As we focus on...
Nasdaq GlobeNewswire
25/10/2023

Velocity aggressively expands MASH/MASLD capabilities with latest site…

• Add two KOLs: Dr Kris Kowdley and Dr Nadege Gunn • Builds on existing MASH/MASLD capabilities at 23 sites globally DURHAM N.C., Oct.25, 2023(GLOBE NEWSWIRE) -- Velocity Clinical Research (“Velocity”), the leading multi-specialty clinical sites business, announced it has acquired Impact Research Institute (Waco, TX) and the clinical trials unit of Liver Institute Northwest (Seattle, WA), aggressively expanding its capabilities in liver disease research, including MASH (metabolic...
Nasdaq GlobeNewswire
25/10/2023

Heroes in the Kitchen Preparing Vegan Meals for Heroes at the Frontlines

Omer Tal, head chef and culinary consultant for Redefine Meat, Ltd. supported this mountainous task by orchestrating an initiative dedicated to serving the vegan/flexitarian soldiers. Chef Tal brought together a collaborative of Israeli foodTech startups, vegan food producers, and 100 volunteers and private chefs. Omer Tal , head chef and culinary consultant for Redefine Meat, Ltd. supported this mountainous task by orchestrating an initiative dedicated to serving the vegan/flexitarian...
PR Newswire
25/10/2023

Alkermes plc Reports Third Quarter 2023 Financial Results

— Company Reiterates Financial Expectations for Full-Year 2023 — — Company Reiterates Financial Expectations for Full-Year 2023 — — Separation of Oncology Business Expected to be Completed inNovember 2023— DUBLIN,Oct. 25, 2023/PRNewswire/ -- Alkermes plc(Nasdaq: ALKS) today reported financial results for the third quarter of 2023. "With solid performance across our proprietary commercial portfolio, the successful settlement of the VIVITROL ®patent litigation, and...
PR Newswire
25/10/2023

Everdrone introduces game-changing multipurpose E2 drone to revolutionize…

Multipurpose capacity for increased serviceWith the new E2 multipurpose drone, emergency deliveries of time-sensitive medical equipment will now be complemented with the possibility of transmitting live hi-res and IR video, adding up to a unique multipurpose solution. Multipurpose capacity for increased serviceWith the new E2 multipurpose drone, emergency deliveries of time-sensitive medical equipment will now be complemented with the possibility of transmitting live hi-res and IR video,...
PR Newswire
25/10/2023

First patient treated in the second dose group in Annexin's RVO study

All six planned patients have now completed treatment in the phase 2 study's first patient group (cohort) where the patients were treated at the lowest dose level, 2 mg/day, for five days. No limiting side effects have been observed in the first cohort and after the recommendation by an independent Safety Review Committee, which evaluates the study based on safety, among other things, the first patient has now been treated in the second cohort of the study, where up to ten patients are planned…
PR Newswire
25/10/2023

International Research Collaboration Aims to Personalise Prevention and…

33 leading international partners, supported by the Innovative Health Initiative (IHI), have teamed up to launch the research consortium iCARE4CVD to better understand cardiovascular disease and optimise future prevention and treatment. By creating one database consisting of data from more than 1 million patients and using artificial intelligence, partners will look for new strategies to shift from a one-size-fits-all approach to personalised care. MAASTRICHT, Netherlands, Oct.25, 2023...
Nasdaq GlobeNewswire
25/10/2023

Oxurion Receives EUR 1.5 Million under Amended Atlas Funding Program; Total of…

Leuven, BELGIUM, Boston, MA, US – October 25, 2023 – 8 am CET– Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next-generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, announced today that it has received EUR 1.5 million in funding under the Subscription Agreement with Atlas Special Opportunities LLC (“Atlas”).This is the second installment of the EUR 3.5 million in unconditional funding agreed with Atlas...
Nasdaq GlobeNewswire
25/10/2023

Vistin Pharma ASA: Third quarter 2023 financial results

Vistin Pharma ASA (Vistin Pharma, OSE: VISTIN) today announces the financial results for the third quarter of 2023.Vistin delivers another strong quarter with all-time high revenue, EBITDA and sales volume. Revenue in the third quarter ended at MNOK 120 compared to MNOK 92 in Q3 2022, a 30% increase. Increased volume from the new production line compared to the same quarter last year has resulted in more volumes available for sale. Revenue YTD ended at MNOK 328 compared to MNOK 194 YTD...
Nasdaq GlobeNewswire
25/10/2023

Vistin Pharma ASA: New CEO appointed

The Board of Directors of Vistin Pharma ASA has appointed Magnus Tolleshaug as the new CEO of Vistin Pharma from 1 stof January 2024. Magnus Tolleshaug is currently the CCO in Vistin Pharma, and will replace the current CEO, Kjell-Erik Nordby. Kjell-Erik has been the CEO of Vistin Pharma since the company was established in 2015 and has decided to retire. Magnus started his career in Vistin 1 stof March 2020 and has been instrumental in delivering Vistin's ambitious growth strategy...
Nasdaq GlobeNewswire
25/10/2023

BioSenic provides third quarter 2023 Business Update

REGULATED INFORMATIONFollowing the in-principle agreement reached with its main creditors in the context of ongoing equity raise process, the focus of BioSenic is now to proceed with fundraising, allowing to start its phase 3 international clinical trial with oral arsenic trioxide (ATO) in the first-line treatment of chronic Graft-versus-Host-Disease (cGvHD).Mont-Saint-Guibert, Belgium, October 25, 2023, 7.00 am CEST – BioSenic provides third quarter 2023 Business Update...
Nasdaq GlobeNewswire
25/10/2023

In-Depth Analysis of Mucopolysaccharidosis Market and its Subtypes…

Key Takeaways from the Mucopolysaccharidosis Market Report Key Takeaways from the Mucopolysaccharidosis Market Report To delve into the mucopolysaccharidosis market landscape in more detail, access the Mucopolysaccharidosis Market Report Mucopolysaccharidosis: Overview and Treatment Mucopolysaccharidosis (MPS), a group of inherited metabolic disorders, involves the buildup of glycosaminoglycans (GAGs) within cells throughout the body due to a deficiency in specific enzymes...
PR Newswire
24/10/2023

Cellectis to Present Pre-Clinical Data on HSPC Gene Therapy Program and…

thannual congress that will take place on October 24-27, 2023 in Brussels, Belgium.The data will be presented in three posters:Intronic editing enables lineage specific expression of therapeutics relevant for HSPC gene therapy (Poster N°646) Presenter:Eduardo Seclen, Senior Scientist & Team Leader, Gene Editing Date/Time:Wednesday October 25 thfrom 18:15 to 19:30 and Thursday October 26 thfrom 19:30 to 20:30 Intronic editing enables lineage specific expression of...
Nasdaq GlobeNewswire
24/10/2023

Snapdragon Chemistry, a Cambrex Company, Recognized with CPhI Pharma Award for…

Snapdragon's award entry, which was reviewed by a global panel of independent industry experts, documented the development of an ultra-high temperature continuous flow manufacturing process for racemization of sotorsib (LUMAKRASTM) P-dione byproduct from Amgen's existing commercial manufacturing process. This technology resulted in a 58% reduction of process mass intensity and is projected to save thousands of metric tons of waste. Snapdragon's award entry, which was reviewed by a global…
PR Newswire
24/10/2023

PHAXIAM Therapeutics obtains authorizations to launch its phase 1 study in…

Approval of study design by French ANSM and Ethics Committee Recruitment of 12 patients expected to start in Q4 2023 in 4 French centersFirst study results expected in mid-2024 Lyon (France) et Cambridge (MA, US), October 24, 2023, at 10:05 pm CEST – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), a biopharmaceutical company developing innovative treatments for resistant bacterial infections,announces the approval of its phase 1 study clinical design in endocarditis...
Nasdaq GlobeNewswire
24/10/2023

IPSEN - Buy-back program - Art 5 of MAR - Week 42 - 2023

Aggregatedpresentationbydayandbymarket Name of issuerIdentificationcodeof issuer (Legal Entity Identifier)Day of transactionIdentificationcodeof financial instrumentAggregated daily volume (in number of shares)Daily weighted average price of the purchased shares *Market (MIC Code) IPSEN549300M6SGDPB4Z94P1116/10/2023FR0010259150258117.59CEUXIPSEN549300M6SGDPB4Z94P1116/10/2023FR00102591501,442117.86XPAR...
Nasdaq GlobeNewswire
24/10/2023

Labstat, A Certified Group Company, Announces Expansion into Europe with New…

"The opening of our Utrecht laboratory signifies an exciting period of growth for Labstat, presenting us with a unique opportunity to extend our top-notch service to our expanding European client base," said Michael Bond, Labstat President. "The new facility allows us to provide superior scientific support locally, meaning shorter turnaround times and more streamlined logistics for our customers." "The opening of ourUtrechtlaboratory signifies an exciting period of…
PR Newswire
24/10/2023
Altri  Comunicati